7/15/2014 7:15:54 AM
In an interview with TheStreet's Adam Feuerstein, David Miller elaborates on his view that Roche (RHHBY +1.3%) has a strong incentive to acquire Exelixis (EXEL +10.7%) in order to capture the full margin of the combination therapy cobimetinib and currently-approved Zelboraf (vemurafenib). He says that the combo regimen could reach peak sales of $1B and should be priced at a premium to Glaxo's (GSK -0.4%) inferior offering of Tafinlar and Mekinist. He believes it will establish itself as the standard of care as a first-line therapy for BRAF-mutated melanoma.
Help employers find you! Check out all the jobs and post your resume.
comments powered by